FDA CAR-T Approval & NICE CGT Framework

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The CAR-T development especially feels like a turning point.

MarcusSame here. We're looking at the FDA's CAR-T approval for solid tumors — a real paradigm shift for oncology evidence generation. Then NICE's updated cell and gene therapy framework — addressing long-standing value assessment challenges. Plus, CMS's proposed 2027 Medicare Advantage Star Ratings changes, and the EU's expansion of joint clinical assessments to non-oncology drugs.

SaraThat second one is interesting to me — the budget impact question there is one the field hasn't fully worked out yet. Cell therapies are fundamentally different from traditional drugs.

MarcusExactly. Let's get into it.

MarcusStarting with the FDA's CAR-T approval for solid tumors. This isn't just another accelerated approval — it's the first CAR-T to show meaningful activity in a solid tumor setting. The data suggests a new frontier for immuno-oncology evidence.

SaraThat's one read — I'd frame it slightly differently. What strikes me is the evidence gap. We're seeing surrogate endpoints where survival data is still maturing. Payers will need real-world evidence to confirm durability and manage budget impact.

MarcusFair point. But what's striking here is the precedent it sets. If CAR-T can cross into solid tumors, it fundamentally reshapes how we think about value for complex biologics. The question becomes: can HTA bodies adapt their frameworks to these one-time, high-cost interventions?

SaraThe part that gives me pause is the budget impact calculation. Even with efficacy, the per-patient cost is astronomical. Health systems will need novel payment models to absorb this. We're seeing early-stage discussions about outcomes-based contracts, but nothing standardized yet.

MarcusThat connects to something I keep coming back to: the R&D investment angle. These therapies represent billions in R&D. The challenge is aligning that investment with sustainable access. What's your take on how payers will approach this?

SaraHonestly, this one caught me off guard. The evidence generation timeline for solid tumors is longer than hematologic malignancies. I wonder if that's the full picture though — will payers accept longer follow-up periods for these therapies? Or will they demand more robust initial data?

MarcusThat's a critical tension. The industry will argue for innovation-friendly pathways, but payers will push for certainty. The solution likely lies in adaptive evidence generation — something the FDA is increasingly open to. What we need now is a transatlantic consensus on evidence standards.

SaraI agree. But let's not overlook the operational hurdles. Health systems don't have the infrastructure to deliver these therapies widely. Access isn't just about pricing — it's about implementation. That's a payer-side concern that industry sometimes underestimates.

MarcusGood point. Moving to NICE's updated cell and gene therapy framework. They've finally acknowledged the unique value proposition of these therapies — particularly for ultra-rare conditions. The framework now includes a higher cost-effectiveness threshold for highly specialized technologies.

SaraThat's fair, though I think payers would see it differently. The threshold increase is welcome, but the real question is whether it will translate to more positive recommendations. NICE still has a history of rejecting high-cost therapies even within the new thresholds. The methodology for budget impact remains opaque.

MarcusExactly. The framework evolution is significant because it recognizes that traditional cost-per-QALY metrics don't capture the full value of curative therapies. But I'm skeptical about how consistently this will be applied. What's your prediction for the first wave of appraisals under this new framework?

SaraI expect cautious optimism. NICE will likely approve a few high-profile therapies to demonstrate the framework works, but maintain strict evidence requirements. The budget impact assessment will be the real test — will they consider the long-term cost savings from curing diseases? Or focus on short-term expenditure?

MarcusThat's the million-dollar question. The industry will need to generate real-world evidence showing downstream cost offsets. But for ultra-rare diseases, that's incredibly challenging. We might see more reliance on modeling assumptions, which payers often distrust.

SaraRight, and from the payer side, we need transparency. How are those models constructed? What assumptions are being made? The black box nature of some cost-effectiveness analyses creates skepticism. NICE's framework update is a step forward, but we need more methodological clarity.

MarcusNow to CMS's proposed changes to Medicare Advantage Star Ratings for 2027. They're expanding quality measures to include social determinants of health and patient experience. This could fundamentally shift how plans compete on value.

SaraThat's interesting timing. With the IRA implementation still unfolding, this feels like CMS trying to move beyond pure cost containment. But the operational implications are massive. How will plans measure social determinants? What data infrastructure is required? These questions remain unanswered.

MarcusWhat strikes me is the potential for unintended consequences. If plans prioritize star ratings over clinical outcomes, we might see gaming of metrics. The industry will need to adapt their evidence strategies to demonstrate impact on these new quality domains.

SaraAbsolutely. And that's where HEOR becomes even more critical. We need robust studies showing how interventions affect not just clinical outcomes, but also patient-reported experience and social factors. This represents a significant expansion of value evidence requirements.

MarcusFinally, the EU's expansion of joint clinical assessments to non-oncology drugs. After the initial oncology wave, they're now covering rare diseases and innovative therapies. This could harmonize evidence generation across member states.

SaraThat's one read — I'd frame it slightly differently. The expansion is welcome, but the capacity constraints are real. HTA bodies are already struggling with oncology assessments. Adding non-oncology drugs could create bottlenecks. The timeline for assessments might lengthen, delaying access.

MarcusFair point. But the harmonization potential is enormous. If done well, it could reduce redundant evidence generation across countries. The challenge will be maintaining methodological rigor while scaling up. What's your take on the impact on small markets?

SaraSmall markets might benefit from earlier access, but they'll have less influence on the assessment process. The risk is that the framework becomes dominated by larger markets' priorities. We need safeguards to ensure diverse perspectives are included. Otherwise, it could exacerbate access disparities.

MarcusThat's a valid concern. The success of this expansion will depend on how well they manage the triage process. Industry will need to prioritize submissions strategically, focusing on therapies with the most compelling evidence profiles.

SaraExactly. And that brings us back to a recurring theme: evidence quality. As these frameworks expand, the bar for evidence will only rise. Companies need to invest in robust HEOR from early development. There's no room for weak evidence anymore.

SaraA lot to think about today. I'll be watching how NICE's new CGT framework translates into actual recommendations and whether we see more positive appraisals for high-cost therapies.

MarcusSame — and for me the thread running through today is the evolution of value frameworks. From CAR-T solid tumors to CMS Star Ratings, we're seeing a fundamental rethink of what constitutes value in healthcare. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.